160 related articles for article (PubMed ID: 37945033)
21. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
He R; Lin F; Deng Z; Yu B
SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
23. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
[TBL] [Abstract][Full Text] [Related]
24. Clinical and functional efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis carrying the N1303K mutation.
Sadras I; Kerem E; Livnat G; Sarouk I; Breuer O; Reiter J; Gileles-Hillel A; Inbar O; Cohen M; Gamliel A; Stanleigh N; Gunawardena T; Bartlett C; Gonska T; Moraes T; Eckford PDW; Bear CE; Ratjen F; Kerem B; Wilschanski M; Shteinberg M; Cohen-Cymberknoh M
J Cyst Fibros; 2023 Nov; 22(6):1062-1069. PubMed ID: 37331863
[TBL] [Abstract][Full Text] [Related]
25. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
Savi D; Lucca F; Tridello G; Meneghelli I; Comello I; Tomezzoli S; Signorini M; Proietti E; Cucchetto G; Volpi S; Cipolli M
Respir Med; 2023; 219():107406. PubMed ID: 37690570
[TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis.
Keens T; Hoffman V; Topuria I; Elder K; Cerf S; Mulder K; Roberts J; Lysinger J; Del Carmen Reyes M; Berdella M; Cairns AM; Jain M; Ganapathy V; Lou Y; Morcos B; Wu C; Sass L;
Heliyon; 2024 Apr; 10(7):e28508. PubMed ID: 38586424
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
29. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
30. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
31. Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.
Fainardi V; Skenderaj K; Ciuni A; Milanese G; Deolmi M; Longo F; Spaggiari C; Sverzellati N; Esposito S; Pisi G
Respir Med; 2023 Sep; 216():107328. PubMed ID: 37321310
[TBL] [Abstract][Full Text] [Related]
32. A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant.
Sawicki GS; Chilvers M; McNamara J; Naehrlich L; Saunders C; Sermet-Gaudelus I; Wainwright CE; Ahluwalia N; Campbell D; Harris RS; Paz-Diaz H; Shih JL; Davies JC
J Cyst Fibros; 2022 Jul; 21(4):675-683. PubMed ID: 35190292
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
[TBL] [Abstract][Full Text] [Related]
34. Non-respiratory health-related quality of life in people with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
Fajac I; Daines C; Durieu I; Goralski JL; Heijerman H; Knoop C; Majoor C; Bruinsma BG; Moskowitz S; Prieto-Centurion V; Van Brunt K; Zhang Y; Quittner A
J Cyst Fibros; 2023 Jan; 22(1):119-123. PubMed ID: 36114142
[TBL] [Abstract][Full Text] [Related]
35. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
36. Effects of elexacaftor/tezacaftor/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI.
Streibel C; Willers CC; Pusterla O; Bauman G; Stranzinger E; Brabandt B; Bieri O; Curdy M; Bullo M; Frauchiger BS; Korten I; Krüger L; Casaulta C; Ratjen F; Latzin P; Kieninger E
J Cyst Fibros; 2023 Jul; 22(4):615-622. PubMed ID: 36635199
[TBL] [Abstract][Full Text] [Related]
37. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
38. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
[No Abstract] [Full Text] [Related]
39. Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation.
Roder L; Simonsen M; Fitzpatrick L; He J; Loucks J
J Manag Care Spec Pharm; 2022 Sep; 28(9):989-996. PubMed ID: 36001103
[No Abstract] [Full Text] [Related]
40. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study.
Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA
Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]